Dr Alexandra Andrews
Chief Operating Officer
PhD Neuroscience, BBMed Sci (Hons1st)
Expertise in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments. Former Director of Operations at NeuroScientific Biopharmaceuticals.
More than 20 years’ experience in trading, investment banking & providing corporate advice. Specialises in providing corporate advice & capital raising services to emerging companies seeking business development opportunities and funding from the Australian market. Managing Director of 1861 Capital and co-founder of investment banking firm, Cygnet Capital.
Director of Public Relations
Pharmacist and consumer health commentator. Leading media health commentator heard each week on television and radio stations across Australia. Extensive knowledge relating to pharmaceutical/ nutraceutical product development, dispensing & marketing in addition to product positioning within the relevant regulatory landscapes (eg. TGA, FDA).
Prof. Allan Cripps AO
Director of Science and Innovation
PhD, BSc (Hons), FAHSM, FASM, FAIMS, FIBMS, FCHSM, MACID
Distinguished academic, clinical scientist and health services leader. Independent Chair of the Children’s Health Research Alliance Board and NonExecutive Director at Bard1 (BD1). Formerly the Pro Vice Chancellor (Health) at Griffith University and currently professor emeritus at Griffith University.
Dr Thomas Duthy
PhD Molecular Microbiology, MBA
Dr Duthy has over 18 years of direct financial market and executive-level/Board experience with ASX listed companies. Nemean Group provides corporate advisory and investor relations services in the Life Sciences and Technology sectors.
MCom, FFin, CPA, GAICD, FGIA/FCG
Experienced company director with over 20 years experience in various roles within the Australian capital markets. Core expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance.